Intralink Spine, Inc. (ILS) was formed to develop, manufacture, and sell an injectable medical device to treat Degenerative Disc Disease (DDD), low back pain, and related spinal diseases. Our medical device stabilizes the spinal joint and decompresses and reduces the strain on the surrounding neural tissues without the high expense and risks associated with surgery. Through the addition of numerous, permanent chemical bonds, the injected reagent increases nutritional flow to the spinal disc, reduces disc bulge under load, and significantly strengthens disc tissue, increasing durability and tear resistance for immediate and long-term treatment of DDD and its associated pathologies. These disorders affect over 15 million people each year in the US alone. A decade of testing indicates that this treatment can make a large segment of spinal surgeries obsolete by providing superior mechanical outcomes via an injection – at a fraction of the cost.
Orthopeutics Awarded 8th US Patent : Orthopeutics’ 8th US patent #8,450,276 will issue May 28, 2013 – covers increasing biological viability for regeneration of spinal discs
Intralink Spine Raising Funds : Intralink Spine is currently raising funds for clinical trials. Check out the most recent executive summary and investment conference presentation. Qualified investors should fill in the Contact Form for more information.